REG - Eco Animal Health Gp - Change of Registered Address

ECO Animal HealthAnnouncement

24/02/2023 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230224:nRSX0405Ra&default-theme=true

RNS Number : 0405R  Eco Animal Health Group PLC  24 February 2023

24 February 2023

 

 

ECO Animal Health Group plc

 

("ECO" or the "Company")

 

Change of Registered Address

 

ECO Animal Health Group plc, a leader in the development, registration and
marketing of pharmaceutical products for global animal health markets
announces today that its registered office, previously situated at 78 Coombe
Road, New Malden, Surrey, KT3 4QS has changed with immediate effect to: The
Grange, 100 High street, London N14 6BN.

 

For further information please contact:

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                   020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 George Tzimas

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Daniel Adams

 Carlo Spingardi

 Equity Developments                                            020 7065 2692

 Hannah Crowe

 Matt Evans

 

 About ECO Animal Health

 ECO Animal Health Group plc researches, develops and commercialises products
 for livestock. Our business strategy is to generate shareholder value by
 achieving the maximum sales potential from the existing product portfolio
 whilst investing in Research and Development ("R&D") for new products,
 particularly vaccines, and seeking to in-license new products.

 

 

 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CROPPURGPUPWGAC